BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31071164)

  • 1. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.
    Wong WJ; Baltay M; Getz A; Fuhrman K; Aster JC; Hasserjian RP; Pozdnyakova O
    PLoS One; 2019; 14(5):e0216810. PubMed ID: 31071164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms.
    Gleitz HFE; Benabid A; Schneider RK
    Curr Opin Hematol; 2021 Sep; 28(5):364-371. PubMed ID: 34232140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
    Jutzi JS; Mullally A
    Front Immunol; 2020; 11():2093. PubMed ID: 32983162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
    Gleitz HFE; Dugourd AJF; Leimkühler NB; Snoeren IAM; Fuchs SNR; Menzel S; Ziegler S; Kröger N; Triviai I; Büsche G; Kreipe H; Banjanin B; Pritchard JE; Hoogenboezem R; Bindels EM; Schumacher N; Rose-John S; Elf S; Saez-Rodriguez J; Kramann R; Schneider RK
    Blood; 2020 Oct; 136(18):2051-2064. PubMed ID: 32726410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis.
    Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
    Leukemia; 2020 May; 34(5):1364-1372. PubMed ID: 31776465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of myeloproliferative neoplasms.
    Skoda RC; Duek A; Grisouard J
    Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
    Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
    Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.
    Longhitano L; Tibullo D; Vicario N; Giallongo C; La Spina E; Romano A; Lombardo S; Moretti M; Masia F; Coda ARD; Venuto S; Fontana P; Parenti R; Li Volti G; Di Rosa M; Palumbo GA; Liso A
    Aging (Albany NY); 2021 Dec; 13(23):25055-25071. PubMed ID: 34905501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
    Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
    Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and myeloproliferative neoplasms.
    Lussana F; Rambaldi A
    J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.